Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
A Presentations and Submissions The committee would like to thank the following people who shared their expertise. PRESENTATIONS December 15, 1999, Washington, D.C. Presentation of the Charge to the Institute of Medicine Committee Mitch Zeller, Food and Drug Administration (current affiliation, American Legacy Foundation Bern Schwetz, Food and Drug Administration March 2, 2000, Washington, D.C. Harm Reduction and Lessons Learned: Historical Perspective and Policy Advice John Slade, University of Medicine and Dentistry at New Jersey School of Public Health Harm Reduction and Lessons Learned: Low Tar and Nicotine Story Don Shopland, National Cancer Institute Tobacco Toxicology Review: Emphasis on Carcinogenesis Steve Hecht, University of Minnesota Exposure Assays David Ashley, Centers for Disease Control and Prevention Nicotine Pharmacology and Toxicology Neal Benowitz, University of California, San Francisco 583
584 APPENDIX A April 25, 2000, Washington, D.C. Risk Perception and Decision Making Paul Slovic, Decision Research, University of Oregon Epidemiology of Low-Tar Cigarettes David Burns, University of California, San Diego Clinical Trial Design Considerations Jack Henningfield, Pinney Associates, Johns Hopkins School of Medicine Janine Pillitteri, Pinney Associates John Hughes, University of Vermont Clinical Indicators of Chronic Obstructive Pulmonary Disease Steve Rennard, University of Nebraska Physical and Chemical Characteristics of Tobacco Smoke Robert Phalen, University of California, Irvine State of Massachusetts Regulation of Tobacco Products Gregory Connolly, Massachusetts Department of Public Health Michael Borgerding, R.J. Reynolds Tobacco Company CONTRIBUTIONS Thoughtful contributions were also provided by the following: Industry Representatives Brown and Williamson Tobacco Company Scott Appleton Sharon Boyse Rufus Honeycutt Tilford Riehl Lorillard Tobacco Company Christopher Coggins and colleagues Chuck Gaworski J. Dan Heck Philip Morris Tobacco Company Richard A. Carchman Bruce D. Davies Hans-Juergen Haussmann Robin D. Kinser Donald E. Leyden George J. Patskan Richard P. Solana Anthony R. Ticker
APPENDIX A 585 R.J. Reynolds Tobacco Company Michael Borgerding J. Donald deBethizy David Doolittle David Iauco Arnold T. Mosberg Seth Moskowitz John H. Robinson Robert L. Suber James E. Swauger Star Scientific, Inc. Scott D. Ballin Jerome H. Jaffe Paul L. Perito GlaxoWellcome Pharmacutical Brenda Jamerson Pharmacia Corporation Mikael Franzon Vibeke Kronborg Smith Kline Beecham Individuals Gregory Dalack, VA Ann Arbor Healthcare System Karl Fagerstrom, Fagerstrom Consulting Nigel Gray, European Institute of Oncology Jack Henningfield, Pinney Associates Thomas Houston, American Medical Association John Hughes, University of Vermont Anne Kirchner, Food and Drug Administration Robert Nilsson, National Chemicals Inspectorate, Sweden Brad Radu, University of Alabama Elsy-Britt Schildt, University Hospital, Sweden Saul Shiffman, University of Pittsburgh and Pinney Associates John Slade, University of Medicine and Dentistry at New Jersey School of Public Health Steven Stellman, American Health Foundation David Sweanor, Smoking and Health Action Foundation, Canada Puzant Torigian Dennis Ole Wik Judy Wilkenfeld, Campaign for Tobacco Free Kids Richard Windsor, University of Alabama